Nextbiomedical, which provides innovative therapeutic materials together with Medtronic, has completed the public offering schedule including subscription.
Nextbiomedical, a developer of innovative therapeutic materials (KI1), announced on the 8th that it conducted a subscription for general investors over two days from the 7th to the 8th, recording a competition rate of 65.83 to 1. The subscription deposit amounted to 238.6 billion KRW.
In the demand forecast conducted for domestic and foreign institutional investors over five days from the 29th of last month to the 2nd, a competition rate of 356.9 to 1 was recorded. The public offering price was set at 29,000 KRW, the upper limit of the desired price range.
The world's first bioresorbable arthritis pain embolic therapeutic material, NexphereF, has obtained Korean and European CE-MDD certifications. Post-market clinical trials are underway in Korea to apply for new medical technology approval. In Europe, multiple dealership and distribution rights contracts have been signed. Post-market clinical trials are about to begin. Recently, the clinical trial plan (IDE) was submitted to the U.S. FDA, and the company plans to enter the U.S. market after clinical trials.
Donhaeng Lee, CEO of Nextbiomedical, said, "We sincerely thank all investors who actively participated, believing in our corporate value and growth potential during the demand forecast and subscription."
Nextbiomedical will be listed on KOSDAQ on the 20th. The listing underwriter is Korea Investment & Securities.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
